The shots, if approved by the agency, would be the first vaccines publicly available against a respiratory virus that kills thousands a year. Some advisers did cite a small but identifiable health risk.
This post first appeared in The New York Times – Business. Read the original article.FDA Panel Recommends 2 RSV Vaccines for Older Adults
The New York Times – Business:
Written by
in
